Hermine I. Brunner

Hermine I. Brunner

Auto-generated profile, based on publicly available information

Hermine I. Brunner

Cincinnati Children's Hospital Medical Center Cincinnati Ohio

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
RVRonald F van Vollenhoven
Ronald F van Vollenhoven
GBGeorge Bertsias
George Bertsias
ADAndrea Doria
Andrea Doria
DIDavid Isenberg
David Isenberg
EMEric Morand
Eric Morand
CACynthia Aranow
Cynthia Aranow
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

27 January 2022 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
AMAlberto Martini
Alberto Martini
DLDaniel Joe Lovell
Daniel Joe Lovell
SASalvatore Albani
Salvatore Albani
HBHermine I. Brunner
Hermine I. Brunner
KHKimme L. Hyrich
Kimme L. Hyrich
NRNicolino Ruperto
Nicolino Ruperto

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
HBHermine I Brunner
Hermine I Brunner
NRNicolino Ruperto
Nicolino Ruperto
ZZZbigniew Zuber
Zbigniew Zuber
CKCaroline Keane
Caroline Keane
OHOlivier Harari
Olivier Harari
FBFabrizio De Benedetti
Fabrizio De Benedetti
Objective To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods This three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW) <30 kg; 8 mg/kg for BW ≥30 kg). At week 16, patients with ≥JIA-American College of Rheumatology (ACR) 30 improvement entered the 24-week, double-blind part 2 after randomisation 1:1 to placebo or tocilizumab (stratified by methotrexate and steroid background therapy) for evaluation of the primary end point: JIA flare, compared with week 16. Patients flaring or completing part 2 received open-label tocilizumab. Results In part 1, 188 patients received tocilizumab (<30 kg: 10 mg/kg (n=35) or 8 mg/kg (n=34); ≥30 kg: n=119). In part 2, 163 patients received tocilizumab (n=82) or placebo (n=81). JIA flare occurred in 48.1% of patients on placebo versus 25.6% continuing tocilizumab (difference in means adjusted for stratification: −0.21; 95% CI −0.35 to −0.08; p=0.0024). At the end of part 2, 64.6% and 45.1% of patients receiving tocilizumab had JIA-ACR70 and JIA-ACR90 responses, respectively. Rates/100 patient-years (PY) of adverse events (AEs) and serious AEs (SAEs) were 480 and 12.5, respectively; infections were the most common SAE (4.9/100 PY). Conclusions Tocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis. Trial registration number: NCT00988221.

1 February 2010 in Rheumatic Disease Clinics of North America
Verified
Journal Article
Closed access
RMRina Mina
Rina Mina
HBHermine I. Brunner
Hermine I. Brunner

5 August 2019 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
GSGrant S. Schulert
Grant S. Schulert
SYShima Yasin
Shima Yasin
BCBrenna Carey
Brenna Carey
CCClaudia Chalk
Claudia Chalk
TDThuy Do
Thuy Do
AGAlexei A. Grom
Alexei A. Grom

1 October 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
HBHermine I Brunner
Hermine I Brunner
CACarlos Abud-Mendoza
Carlos Abud-Mendoza
DVDiego O Viola
Diego O Viola
IPInmaculada Calvo Penades
Inmaculada Calvo Penades
DLDeborah Levy
Deborah Levy
NRNicolino Ruperto
Nicolino Ruperto
Objectives This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE). Methods Patients (5 to 17 years) were randomised to belimumab 10 mg/kg intravenous or placebo every 4 weeks, plus standard SLE therapy. Primary endpoint: SLE Responder Index (SRI4) response rate (Week 52). Key major secondary endpoints: proportion of patients achieving the Paediatric Rheumatology International Trials Organisation/American College of Rheumatology (PRINTO/ACR) response using 50 and ‘30 alternative’ definitions (Week 52), and sustained response (Weeks 44 to 52) by SRI4 and Parent Global Assessment of well-being (Parent-global). Safety and pharmacokinetics were assessed. Study not powered for statistical testing. Results Ninety-three patients were randomised (belimumab, n=53; placebo, n=40). At Week 52, there were numerically more SRI4 responders with belimumab versus placebo (52.8% vs 43.6%; OR 1.49 (95% CI 0.64 to 3.46)). PRINTO/ACR 30 alternative (52.8% vs 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses were more frequent with belimumab than placebo, as were sustained responses for SRI4 (belimumab, 43.4%; placebo, 41.0%; OR 1.08 (95% CI 0.46 to 2.52)) and Parent-global (belimumab, 59.1%; placebo, 33.3%; OR 3.49 (95% CI 1.23 to 9.91)). Serious adverse events were reported in 17.0% of belimumab patients and 35.0% of placebo patients; one death occurred (placebo). Week-52, geometric mean (95% CI) belimumab trough concentration was 56.2 (45.2 to 69.8) µg/mL. Conclusion The belimumab intravenous pharmacokinetics and benefit–risk profile in cSLE are consistent with adult belimumab studies and the 10 mg/kg every 4 weeks dose is appropriate. Trial registration number NCT01649765.